- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01977586
Functional Imaging in the Assessment of mRCC Response to Sunitinib
Pilot Study to Evaluate the Feasibility of Functional MRI in Metastatic Renal Cell Carcinoma (mRCC) With Test--retest Repeatability and Early Response Assessment
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Renal cell carcinoma (RCC) is a highly vascularized tumour that is dependent on new vessel formation (angiogenesis) for growth and spread beyond the kidney (metastases). In recent years a new class of drugs have been developed which target the formation of this blood supply, stopping tumour growth and resulting in increased survival. These anti-angiogenic drugs such as Sunitinib, Pazopanib, Axitinib and Everolimus are now the standard of care in metastatic RCC (mRCC) in the United Kingdom.
Currently we assess if cancers are responding to treatment by looking at changes in the size of the tumour and metastases using computed tomography. However, the positive effects of drugs such as sunitinib do not always show a change in size, particularly early in treatment. Therefore we need to develop alternative methods for assessing if patients are responding in order to optimise individual management plans and prevent unnecessary toxicity and cost.
The aim of this study is to assess if three different functional magnetic resonance imaging (MRI) techniques are able to predict which patients will derive benefit from anti-angiogenic therapy early in their treatment. The study will recruit patients with mRCC who are going to be treated with anti-angiogenic drugs. These patients will have an MRI scan before they commence treatment and then a further scan after one treatment cycle (4 weeks) in addition to their normal clinical follow-up. The sequences being evaluated (arterial spin labeling, diffusion-weighted imaging and dynamic contrast imaging) look at the blood supply to the cancer and it is expected that there will be different changes in this blood supply in patients who are benefiting from treatment compared to those who are not responding. Early knowledge of response will help doctors choose the most appropriate treatment option for each individual patient.
Consenting patients with treatment naïve metastatic clear cell RCC will be recruited to the study. Before commencing anti-angiogenic therapy, patients will undergo 3 Tesla MRI covering the primary tumour or largest metastatic deposit identified from their staging CT examination if prior nephrectomy has been performed. Following 4 weeks of therapy (one treatment cycle), patients will undergo repeat MR imaging using the same protocol.
Studientyp
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
London, Vereinigtes Königreich
- Imperial College Healthcare NHS Trust
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Patients with newly diagnosed (i.e. treatment naive) metastatic clear cell renal cell carcinoma judged by their treating physician to have the potential to derive benefit from anti-angiogenic therapy
- Histopathologically confirmed clear cell renal cell carcinoma
- Male or female aged 18 years or older
Exclusion Criteria:
- Previous medical treatment for renal cancer
- Cardiac pacemaker or other contra-indication to magnetic resonance imaging
- Contra-indication to intravenous Gadolinium
- Pregnancy or breastfeeding
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Diagnose
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Metastatic renal cell carcinoma
Patients with clear cell renal cell carcinoma treated with anti-angiogenic therapies
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
To determine if functional MRI techniques are able to detect treatment-related changes in patients with metastatic renal cell carcinoma treated with sunitinib
Zeitfenster: At baseline and following one treatment cycle (expected 4 weeks) with anti-angiogenic therapy
|
At baseline and following one treatment cycle (expected 4 weeks) with anti-angiogenic therapy
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Repeatability of Arterial Spin Label and Diffusion Weighted MRI parameters
Zeitfenster: At baseline MRI scan
|
At baseline MRI scan
|
Changes in imaging parameters with treatment
Zeitfenster: At baseline and following one treatment cycle (expected 4 weeks) with anti-angiogenic therapy
|
At baseline and following one treatment cycle (expected 4 weeks) with anti-angiogenic therapy
|
Correlation of imaging parameters with progression free survival
Zeitfenster: Time from study enrolment to progression assessed by RECIST v1.1 on computed tomography performed after every three treatment cycles (up to 36 months)
|
Time from study enrolment to progression assessed by RECIST v1.1 on computed tomography performed after every three treatment cycles (up to 36 months)
|
Correlation of imaging parameters with overall survival
Zeitfenster: Time from study enrolment to date of death from any cause (up to 36 months)
|
Time from study enrolment to date of death from any cause (up to 36 months)
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Nishat Bharwani, MRCP FRCR, Imperial College Healthcare NHS Trust
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 13SM0754
- 13/LO/1182 (Andere Kennung: REC Reference Number)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Metastasierendes Nierenzellkarzinom
-
Bradley A. McGregor, MDBristol-Myers Squibb; ExelixisRekrutierungNierenzellkarzinom | Chromophobes Nierenzellkarzinom | Papilläres Nierenzellkarzinom | Nicht klassifiziertes Nierenzellkarzinom | Collecting Duct Renal Cell Carcinoma | Translokation Nierenzellkarzinom | Nicht resezierbares fortgeschrittenes Nierenzellkarzinom | Metastasierendes Ncc-NierenzellkarzinomVereinigte Staaten
-
Memorial Sloan Kettering Cancer CenterAktiv, nicht rekrutierendChromophobes Nierenzellkarzinom | Papilläres Nierenzellkarzinom | Nicht klassifiziertes Nierenzellkarzinom | Fortgeschrittenes oder metastasiertes nicht-klarzelliges Nierenzellkarzinom | Fumarathydratase-defizientes Nierenzellkarzinom | Succinat-Dehydrogenase-defizientes Nierenzellkarzinom | Collecting Duct Renal Cell CarcinomaVereinigte Staaten
Klinische Studien zur Magnetresonanztomographie (MRT)
-
The Affiliated Hospital Of Guizhou Medical UniversityAktiv, nicht rekrutierend
-
Martin-Luther-Universität Halle-WittenbergAbgeschlossenDiabetes Mellitus | Diabetische Polyneuropathie | Diabetische GastropareseDeutschland
-
Cedars-Sinai Medical CenterAbgeschlossenHerniation der HalswirbelsäuleVereinigte Staaten
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RekrutierungGliom | GehirnmasseVereinigte Staaten
-
Universiteit AntwerpenUniversity Hospital, Antwerp; Cliniques universitaires Saint-Luc- Université...RekrutierungHämophilie A | Hämophilie BBelgien
-
University Hospital, ToursAbgeschlossenBehandlungsresistente Depression | LachgasFrankreich